Výstupy z onkologických registrů v odborné literatuře

Bráno podle výše impakt faktoru je zcela jistě nejzajímavějším výstupem článek založený na datech registru RENIS s názvem Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis, který vyšel v časopisu European Urology (IF 16,265).

Nejvíce článků vzniklo na analýzách z registru TULUNG (celkem 6), u registrů CORECT a RENIS to bylo po 2 článcích.

Registr CORECT:

• Kiss I, Mlčochová J, Bortlíček Z, Poprach A, Drábek J, Vychytilová P, Svoboda M, Büchler T, Batko S, Ryška A, Hajdúch M, Slabý O. Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients. Anticancer Research 2016; 36(9): 4955-4959.
• Fiala O, Buchler T, Mohelnikova-Duchonova B, Melichar B, Matejka VM, Holubec L, Kulhankova J, Bortlicek Z, Bartouskova M, Liska V, Topolcan O, Sedivcova M, Finek J. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumor Biology 2016; 37(5): 6823-6830.

Registr RENIS:

• Büchler T, Bortlíček Z, Poprach A, Pavlík T, Veškrnová V, Honzírková M, Zemanová M, Fiala O, Kubáčková K, Slabý O, Svoboda M, Vyzula R, Dušek L, Melichar B. Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis. European Urology 2016; 70(3): 469-475.
• Poprach A, Lakomý R, Bortlíček Z, Melichar B, Pavlík T, Slabý O, Vyzula R, Svoboda M, Kiss I, Študentová H, Zemanová M, Fiala O, Kubáčková K, Dušek L, Hornová J, Büchler T. Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice. Drugs & Aging 2016; 33(9): 655-663.

Registr TULUNG:

• Fiala O, Pesek M, Finek J, Racek J, Minarik M, Benesova L, Bortlicek Z, Sorejs O, Kucera R, Topolcan O. Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib. Neoplasma 2016; 63(3): 471-476.
• Fiala O, Pesek M, Finek J, Svaton M, Minarik M, Benesova L, Bortlicek Z, Kucera R., Topolcan O. Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene. Anticancer Research 2016; 36(1): 447-453.
• Fiala O, Pesek M, Finek J, Svaton M, Sorejs O, Bortlicek Z, Kucera R, Topolcan O. Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy. Anticancer Research 2016; 36(1): 461-466.
• Fiala O, Pesek M, Finek J, Minarik M, Benesova L, Sorejs O, Svaton M, Bortlicek Z, Kucera R, Topolcan O. Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC. Anticancer Research 2016; 36(1): 455-460.
• Fiala O, Pesek M, Finek J, Topolčan O, Racek J, Svaton M, Kucera R, Minarik M, Benesova, L, Bortlicek Z, Chloupkova R, Poprach A, Buchler T. Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib. Anticancer Research 2016; 36(5): 2459-2465.
• Svaton M, Fiala O, Pesek M, Bortlicek Z, Minarik M, Benesova L, Topolcan O. The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy. Anticancer Research 2016; 36(3): 1077-1082.

4. 5. 2017

Zpět